

Table 1 ClinPK checklist^a of information to be included when reporting a clinical pharmacokinetic study.

[illegible]



Table1. (Continued)

Table1. (Continued)															
Authors and Items	Meagher et al. (2003)	Whiteho use et al. (2005)	Abe et al. (2009)	Swobod a et al. (2010)	Sasaki et al. (2011)	Tsuji et al. (2013)	Matsumo to et al. (2014)	Luque et al. (2014)	Dong et al. (2016)	Taubert et al. (2016)	Minichm ayr et al. (2017)	Tsuji et al. (2017)	Wicha et al. (2017)	Ide et al. (2018)	Allegr a et al. (2018)
No. of subjects and observations	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
schematic of the final model	+	-	-	-	+	-	-	-	-	-	+	+	-	-	-
table of the final model parameters	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
final model evaluation plots	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
summary of the model-building process and the derived final model	+	+	+	-	+	+	+	+	+	+	+	+	+	-	+
plot of concentrations vs. time and/or effects vs. concentrations	-	+	+	+	-	-	+	+	-	+	+	-	-	+	+
Discussion/conclusion															
study limitations	-	-	-	+	-	+	+	+	+	+	+	+	-	+	+
study findings	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Compliance rate (%)	82.9	82.9	68.6	80.0	80.0	85.7	82.9	85.7	77.1	85.7	97.1	85.7	85.7	82.9	88.6

Table1. (Continued)															
Authors and Items	Strydom et al. (2019)	Crass et al. (2019)	Xie et al. (2019)	Thibaul t et al. (2018)	Li et al. (2019)	Garcia- Prats et al. (2019)	Ogami et al. (2019)	Wang et al. (2016)	Alghamdi et al. (2016)	Soraluc e et al. (2017)	Zhang et al. (2020)	Ehmann et al. (2020)	Wang et al. (2020)	Blackm an et al. (2021)	Yang et al. (2021)
Title/abstract															
drug and patient population	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
name of the drug(s) studied	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
route of administration	-	-	+	+	-	-	-	-	-	-	-	+	-	+	-
population studied	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
primary objective	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
major findings	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Background															
pharmacokinetic data	-	+	+	+	+	+	+	-	-	+	+	+	-	+	+
study rationale	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
specific objectives/hypotheses	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Methods															
eligibility criteria	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
co-administration or food	-	-	-	+	-	+	-	+	-	-	+	-	-	-	-
dosing	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
formulation	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
sampling schedule	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+

Table1. (Continued)															
Authors and Items	Strydom et al. (2019)	Crass et al. (2019)	Xie et al. (2019)	Thibaul t et al. (2018)	Li et al. (2019)	Garcia- Prats et al. (2019)	Ogami et al. (2019)	Wang et al. (2016)	Alghamdi et al. (2016)	Soraluc e et al. (2017)	Zhang et al. (2020)	Ehmann et al. (2020)	Wang et al. (2020)	Blackm an et al. (2021)	Yang et al. (2021)
bioanalytical methods	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
methods for handling missing data	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-
modeling software	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
statistical methods and software	+	+	+	-	+	+	+	-	+	+	-	-	+	-	-
candidate structural models	+	+	+	+	+	-	+	+	+	-	+	+	+	+	-
residual error structure	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
methods for base model determination	+	+	+	+	+	-	+	-	+	+	+	+	+	+	+
methods for base model evaluation	+	+	+	+	+	-	+	-	+	+	+	+	+	+	+
covariates analysis strategy	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
methods for final model evaluation	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
distribution of individual model parameters	-	+	+	+	-	-	+	+	+	+	+	-	+	+	+
estimation method(s) used	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+

Table1. (Continued)															
Authors and Items	Strydom et al. (2019)	Crass et al. (2019)	Xie et al. (2019)	Thibaul t et al. (2018)	Li et al. (2019)	Garcia- Prats et al. (2019)	Ogami et al. (2019)	Wang et al. (2016)	Alghamdi et al. (2016)	Soraluc e et al. (2017)	Zhang et al. (2020)	Ehmann et al. (2020)	Wang et al. (2020)	Blackm an et al. (2021)	Yang et al. (2021)
Results															
population characteristic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
No. of subjects and observations	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
schematic of the final model	+	+	-	-	-	-	-	-	-	-	-	+	-	-	-
table of the final model parameters	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
final model evaluation plots	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
summary of the model-building process and the derived final model	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
plot of concentrations vs. time and/or effects vs. concentrations	+	+	-	+	+	+	+	+	-	+	+	+	-	+	+
Discussion/conclusion															
study limitations	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+
study findings	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Compliance rate (%)	82.9	91.4	88.6	91.4	85.7	80.0	91.4	77.1	85.7	82.9	88.6	85.7	82.9	88.6	82.9

 : Meet report requirements (record 1 score);  : Not reported (record zero score); Compliance rate (%) = (sum of reported items / sum of all items) × 100%;

a: The ClinPK checklist was established based on previous guidelines for pharmacokinetics (PK) reports to evaluate the quality of the population PK report.